Management of Locally Advanced Pancreatic Cancer
暂无分享,去创建一个
elliot k fishman | M. Falconi | S. Thayer | Jin He | M. Weiss | C. Are | V. Groot | A. Blair | B. Reames | J. Padussis | R. Krell | G. Gemenetzis
[1] Y. Mou,et al. Laparoscopic pancreaticoduodenectomy for pancreatic cancer: a hope or hype? , 2020, Hepatobiliary surgery and nutrition.
[2] B. Erickson,et al. Importance of Normalization of CA19-9 Levels Following Neoadjuvant Therapy in Patients With Localized Pancreatic Cancer. , 2020, Annals of surgery.
[3] J. Kleeff,et al. Do we need sequential local therapy following neoadjuvant chemotherapy for locally advanced pancreatic cancer? , 2019, EClinicalMedicine.
[4] J. Cameron,et al. Survival in Locally Advanced Pancreatic Cancer After Neoadjuvant Therapy and Surgical Resection. , 2019, Annals of surgery.
[5] M. Ducreux,et al. Opinions and use of neoadjuvant therapy for resectable, borderline resectable, and locally advanced pancreatic cancer: international survey and case-vignette study , 2019, BMC Cancer.
[6] R. J. Haas,et al. Multicentre study of multidisciplinary team assessment of pancreatic cancer resectability and treatment allocation , 2019, The British journal of surgery.
[7] W. Harmsen,et al. Factors Predicting Response, Perioperative Outcomes, and Survival Following Total Neoadjuvant Therapy for Borderline/Locally Advanced Pancreatic Cancer. , 2019, Annals of surgery.
[8] Yuman Fong,et al. Robotic surgery trends in general surgical oncology from the National Inpatient Sample , 2018, Surgical Endoscopy.
[9] M. Reni,et al. A randomised phase 2 trial of nab-paclitaxel plus gemcitabine with or without capecitabine and cisplatin in locally advanced or borderline resectable pancreatic adenocarcinoma. , 2018, European journal of cancer.
[10] M. Makary,et al. Circulating Tumor Cells Dynamics in Pancreatic Adenocarcinoma Correlate With Disease Status: Results of the Prospective CLUSTER Study , 2018, Annals of surgery.
[11] M. Makary,et al. Is a Pathological Complete Response Following Neoadjuvant Chemoradiation Associated With Prolonged Survival in Patients With Pancreatic Cancer? , 2018, Annals of surgery.
[12] T. Liang,et al. Evaluation and proposal of novel resectability criteria for pancreatic cancer established by the Japan Pancreas Society. , 2018, Surgery.
[13] L. Schwartz,et al. Alliance for clinical trials in oncology (ALLIANCE) trial A021501: preoperative extended chemotherapy vs. chemotherapy plus hypofractionated radiation therapy for borderline resectable adenocarcinoma of the head of the pancreas , 2017, BMC Cancer.
[14] F. Rocha,et al. Surgical strategies and novel therapies for locally advanced pancreatic cancer , 2017, Journal of surgical oncology.
[15] J. Cameron,et al. Circulating Tumor Cell Phenotype Predicts Recurrence and Survival in Pancreatic Adenocarcinoma , 2016, Annals of surgery.
[16] J. Cameron,et al. Circulating Tumor Cells Expressing Markers of Tumor-Initiating Cells Predict Poor Survival and Cancer Recurrence in Patients with Pancreatic Ductal Adenocarcinoma , 2016, Clinical Cancer Research.
[17] T. Conroy,et al. FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis. , 2016, The Lancet. Oncology.
[18] J. Kench,et al. Meta‐analysis of radical resection rates and margin assessment in pancreatic cancer , 2015, The British journal of surgery.
[19] D. Urbach. Pledging to Eliminate Low-Volume Surgery. , 2015, The New England journal of medicine.
[20] S. Hendren,et al. Surgical Referral for Colorectal Liver Metastases: A Population-Based Survey , 2015, Annals of Surgical Oncology.
[21] Jin He,et al. A comparison of open and minimally invasive surgery for hepatic and pancreatic resections using the Nationwide Inpatient Sample. , 2014, Surgery.
[22] K. Lillemoe,et al. Does regional variation impact decision-making in the management and palliation of pancreatic head adenocarcinoma? Results from an international survey. , 2014, Canadian journal of surgery. Journal canadien de chirurgie.
[23] David Goldstein,et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. , 2013, The New England journal of medicine.
[24] J. Cameron,et al. Resection of borderline resectable pancreatic cancer after neoadjuvant chemoradiation does not depend on improved radiographic appearance of tumor–vessel relationships , 2013, Journal of Radiation Oncology.
[25] B. Lapuyade,et al. An evaluation of the accuracy of CT when determining resectability of pancreatic head adenocarcinoma after neoadjuvant treatment. , 2013, European journal of radiology.
[26] K. Lillemoe,et al. Pancreatic Ductal Adenocarcinoma: Is There a Survival Difference for R1 Resections Versus Locally Advanced Unresectable Tumors? What Is a “True” R0 Resection? , 2013, Annals of surgery.
[27] Justin B. Dimick,et al. Hospital Volume and Operative Mortality in the Modern Era , 2013, Annals of surgery.
[28] Jeffrey E. Lee,et al. Response of borderline resectable pancreatic cancer to neoadjuvant therapy is not reflected by radiographic indicators , 2012, Cancer.
[29] G. Abel,et al. Increasing response rates from physicians in oncology research: a structured literature review and data from a recent physician survey , 2012, British Journal of Cancer.
[30] N. D. Merrett,et al. The prognostic and predictive value of serum CA19.9 in pancreatic cancer , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.
[31] Pierre Michel,et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. , 2011, The New England journal of medicine.
[32] A. Jemal,et al. Cancer Statistics, 2009 , 2009, CA: a cancer journal for clinicians.
[33] M. Reni,et al. Carbohydrate antigen 19‐9 change during chemotherapy for advanced pancreatic adenocarcinoma , 2009, Cancer.
[34] Derrick Wong,et al. Serum CA19-9 Decline Compared to Radiographic Response as a Surrogate for Clinical Outcomes in Patients With Metastatic Pancreatic Cancer Receiving Chemotherapy , 2008, Pancreas.
[35] N. Ahuja,et al. What constitutes a "high-volume" hospital for pancreatic resection? , 2008, Journal of the American College of Surgeons.
[36] M. Levy,et al. International differences in end-of-life attitudes in the intensive care unit: results of a survey. , 2005, Archives of internal medicine.
[37] J. Birkmeyer,et al. Surgeon volume and operative mortality in the United States. , 2003, The New England journal of medicine.
[38] J. Birkmeyer,et al. Hospital Volume and Surgical Mortality in the United States , 2002 .
[39] A. Jemal,et al. Cancer statistics, 2019 , 2019, CA: a cancer journal for clinicians.
[40] Jeffrey W. Clark,et al. Predictors of Resectability and Survival in Patients With Borderline and Locally Advanced Pancreatic Cancer who Underwent Neoadjuvant Treatment With FOLFIRINOX , 2019, Annals of surgery.
[41] Jeffrey W. Clark,et al. "Radiological and Surgical Implications of Neoadjuvant Treatment With FOLFIRINOX for Locally Advanced and Borderline Resectable Pancreatic Cancer." , 2017, Annals of surgery.
[42] A. Shields,et al. F-Fluorodeoxyglucose Positron Emission Tomography to Monitor Clinical Outcomes in Patients Treated With Neoadjuvant Chemo-Radiotherapy for Locally Advanced Pancreatic Cancer , 2010 .
[43] L. Tanoue. Cancer Statistics, 2009 , 2010 .
[44] N. Dubrawsky. Cancer statistics , 1989, CA: a cancer journal for clinicians.